PotentiaMetrics

PotentiaMetrics PotentiaMetrics is changing the world one decision at a time by providing trusted and actionable hea

PotentiaMetrics provides cloud-based, big data and advanced analytics platforms that reveal personalized and predictive insights.

Healthcare has a data problem. But it may not be the problem you think.Healthcare doesn't suffer from a shortage of data...
10/13/2026

Healthcare has a data problem. But it may not be the problem you think.

Healthcare doesn't suffer from a shortage of data.

We generate enormous amounts of it.
- Claims.
- Electronic health records.
- Registries.
- Clinical trials.
- Lab results.
- Imaging.
- Utilization data.
- Patient-reported information.

The challenge is increasingly something else: How do we turn all of that data into something useful at the moment a decision needs to be made?

Collecting data isn't the same as creating evidence. And having evidence isn't the same as generating insight. And insight only creates value when it can inform a decision.

Think of it as a progression: DATA → EVIDENCE → INSIGHT → DECISION

Data tells us what was recorded. Evidence helps us determine what those observations can reliably tell us. Insight puts that evidence into context.

And a decision is where that information has the opportunity to affect what happens next.

That last mile may be one of healthcare analytics' biggest challenges.

A dataset containing millions of patient records is extraordinarily valuable. But the person making a treatment decision doesn't need millions of records. They need to understand what those records can tell them about the decision in front of them. That's the problem PotentiaMetrics is working to solve.

Capire360 transforms real-world oncology outcomes data into structured, usable insight, providing visibility into how treatment options perform across similar patient populations and how outcomes, utilization, and cost vary between approaches.

Because the future of healthcare analytics isn't simply about having more information. It's about closing the distance between information and action.

We don't necessarily need another dashboard telling us what happened. We need better ways to make what happened useful for what happens next.

A guideline can tell you what is appropriate. Outcomes data can add context about what happened.Clinical guidelines are ...
10/08/2026

A guideline can tell you what is appropriate. Outcomes data can add context about what happened.

Clinical guidelines are foundational to high-quality cancer care.

They synthesize evidence and expert consensus to help clinicians understand appropriate approaches to diagnosis and treatment.

Clinical trials provide another essential layer, helping establish the safety and efficacy of treatments under defined conditions.

Then there is clinical judgment.

The expertise required to take evidence and determine what it means for the individual patient sitting in front of you.

And increasingly, another source of information can contribute to that picture: real-world outcomes.

Real-world evidence isn't a replacement for guidelines. It isn't a replacement for clinical trials. And it certainly isn't a replacement for the physician. It answers a different question.

A guideline can help establish: What is medically appropriate?

A clinical trial can help us understand: What can happen under defined study conditions?

Real-world outcomes can add context about: What has happened when treatments were used among actual patients in routine care?

And the patient contributes something none of those sources can provide: What matters to me?

Those perspectives don't need to compete. They can complement one another.

That's particularly important when more than one treatment approach may be medically reasonable.

Capire360 is designed to operate within that evidence ecosystem, not outside it. Its current positioning is NCCN-aligned and explicitly designed not to contradict guidelines, while adding real-world outcomes context based on patient characteristics including age, comorbidities, cancer type, and stage.

At PotentiaMetrics, we believe the future of evidence-based care isn't about choosing one source of evidence over another.

It's about understanding what each can tell us, and bringing those perspectives together in ways that make evidence more meaningful for the decision at hand.

Guidelines provide direction.
Clinical trials establish evidence.
Clinical judgment applies expertise.
Real-world outcomes add context.
Patients bring their goals and values.
Better decisions make room for all of them.

Variation isn't automatically bad. Unexplained variation is worth understanding.Healthcare spends a lot of time talking ...
10/06/2026

Variation isn't automatically bad. Unexplained variation is worth understanding.

Healthcare spends a lot of time talking about variation.

- Variation in treatment.
- Variation in utilization.
- Variation in outcomes.
- Variation in cost.

And it's tempting to assume that variation itself is the problem.

But different care isn't necessarily inappropriate care.

Two patients with the same cancer diagnosis may appropriately receive different treatments because they aren't actually the same patient.

Their age may differ. Their cancer may have different characteristics. One may have significant comorbidities. Their previous treatments may be different. Their goals, preferences, and tolerance for particular tradeoffs may be different.

In those cases, variation may reflect exactly what we want healthcare to do: respond to the individual.

The more important question is whether we understand why variation exists.

When clinically viable treatment options can differ substantially in cost, understanding variation requires looking beyond the dollar amount and examining the outcomes, utilization, patient characteristics, and treatment decisions associated with it. PotentiaMetrics' current Capire360 materials explicitly connect treatment-level variation with those dimensions.

A higher-cost treatment isn't automatically inappropriate, and a lower-cost treatment isn't automatically better.

Identical treatment for every patient isn't the goal. The opportunity is to distinguish meaningful variation from variation that may warrant a closer look. That requires better visibility into what happened, to whom, under what circumstances, and with what outcomes.

At PotentiaMetrics, we believe real-world evidence can help healthcare organizations move beyond simply identifying variation toward understanding it.

If two treatments produce similar outcomes, should cost become part of the conversation?It’s an uncomfortable question i...
10/02/2026

If two treatments produce similar outcomes, should cost become part of the conversation?

It’s an uncomfortable question in healthcare. And maybe that’s exactly why it’s worth asking.

Imagine two treatments are both clinically appropriate for a patient. The expected outcomes are similar.

But the treatments differ in other ways. Side effects. Time in treatment. Monitoring requirements. Potential complications. Impact on quality of life. Utilization. And cost.

Should cost be part of the conversation?

The answer shouldn't simply be: choose the cheaper treatment, because cost alone doesn't define value. But, ignoring cost entirely doesn't define value either.

In oncology, a treatment decision can have implications far beyond the price of the therapy itself. It can influence downstream utilization, supportive care, hospitalizations, time away from work, caregiver burden, and the overall experience of treatment.

And two treatments that appear similar at first glance may look very different when we consider the whole picture.

That's why meaningful comparison requires context.

- What are the expected outcomes?
- What are the risks and tradeoffs?
- What matters most to this patient?
- What does real-world experience tell us about people with similar characteristics?
- And what resources are associated with each approach?

At PotentiaMetrics, our goal isn't fewer treatments. It's better-informed treatment decisions. Capire360 brings together real-world outcomes with visibility into utilization and cost, helping make differences across treatment options easier to understand.

Because value-based cancer care shouldn't mean choosing the least expensive option. It should mean having enough information to understand the value of the options available.

And when two clinically appropriate treatments offer similar outcomes, cost may not make the decision. But it can be part of the conversation and context.

The most expensive decision in cancer care may happen before the first claim.Health plans have become increasingly sophi...
09/30/2026

The most expensive decision in cancer care may happen before the first claim.

Health plans have become increasingly sophisticated at understanding healthcare utilization.

Claims data can show where money was spent. Where utilization occurred. Where costs are rising. Where variation exists across populations, providers, and treatment pathways.

But in oncology, there is a fundamental challenge:

By the time the cost appears in the claims data, one of the decisions driving it has already been made.

The treatment has been selected.

And that decision can shape much of what follows—from the initial cost of therapy to subsequent utilization, supportive care, adverse-event management, hospitalizations, and total cost of care.

For organizations accountable for both quality and cost, that creates an important question:

What if we could bring better information upstream—before the treatment decision is made?

Cancer treatment isn't always a choice between one appropriate option and one inappropriate option.

There may be multiple clinically reasonable approaches, with different expected outcomes, risks, tradeoffs, utilization patterns, and costs.

The goal isn't to choose the least expensive treatment.

It's to make the value of each option more visible when the decision is actually being made.

That's where real-world outcomes can play an important role.

Capire360 uses data from approximately 2.2 million oncology patients to provide visibility into how treatment options have performed across similar patient populations, including differences in outcomes, utilization, and cost.

For health plans, ACOs, and other organizations operating under value-based models, that changes the timing of analytics.

Instead of only asking:

Where did we spend?

We can begin asking: Where are the decisions that will determine what happens next?

Because retrospective analytics are essential for understanding what already happened.

But some of the greatest opportunities to influence outcomes and total cost of care exist before those outcomes become retrospective.

At PotentiaMetrics, we believe the next evolution of healthcare analytics is bringing actionable real-world insight closer to the point of decision.

By the time you see the cost, the decision has already happened.

09/30/2026

PotentiaMetrics has appointed Marcus Thygeson, MD, MPH, as Chief Medical Officer, bringing extensive experience in clinical leadership, healthcare innovation and person-centered care.

Dr. Thygeson will guide the company’s clinical strategy as it expands its Personalized Shared Decision Making approach across the healthcare ecosystem.

CMS’s proposed changes to G2211 may look like a coding update. But for ACOs, the implications could be much bigger.Our C...
09/30/2026

CMS’s proposed changes to G2211 may look like a coding update. But for ACOs, the implications could be much bigger.

Our Chief Growth Officer, Sheri Rodriguez, co-authored a new piece with Kelly Conroy of Pinnacle Healthcare Consulting examining what the proposed change could mean for ACOs, from near-term reimbursement and beneficiary attribution to benchmarks, shared savings, and the broader direction of value-based care.

The bigger signal? CMS continues to look for ways to connect payment more closely to the work of managing quality, outcomes, and total cost of care.

For ACO leaders thinking about their strategy for 2027 and beyond, this is one worth reading.

Read the full article: https://askphc.com/the-g2211-change-every-aco-should-read-before-its-final-its-a-signal/

Introduction CMS just proposed a change that every ACO should take a close look at. It would not take effect until 2027, but it gives us a clear sense of...

Comorbidities aren't a footnote in cancer care.Cancer doesn't arrive in isolation.A person diagnosed with cancer may als...
09/28/2026

Comorbidities aren't a footnote in cancer care.

Cancer doesn't arrive in isolation.

A person diagnosed with cancer may also be living with diabetes. Heart disease. Kidney disease. COPD. Hypertension. Or several chronic conditions at the same time.

Those conditions don't disappear when cancer becomes the focus of care.

And they can matter when we try to understand what a treatment, and its potential outcomes, could look like for an individual patient.

Consider two people with the same cancer diagnosis.

One is 50 and otherwise healthy.

The other is 70 and managing three chronic health conditions.

The second patient isn't simply an older version of the first.

Their overall health is different. Their ability to tolerate treatment may be different. Their competing health risks may be different. And the outcomes observed among healthier patients may not provide the full context needed to understand what could happen in their situation.

Yet when we rely primarily on broad population averages, some of that complexity can disappear.

That's why comorbidity matters in real-world evidence.

At PotentiaMetrics, Capire360 incorporates comorbidity through the ACE-27 comorbidity index, alongside factors including age, s*x, ethnicity, cancer type, and stage. Those characteristics are used with real-world oncology outcomes to provide more relevant context around treatment options.

Because personalization in cancer care shouldn't stop at knowing the cancer.

It should include understanding the person who has it.

Clinical trials and population-level evidence remain essential. But real patients are complex, and real-world outcomes give us another way to examine that complexity.

A diagnosis tells us what disease we're treating.

The rest of the patient's health helps tell us who we're treating.

And both matter.

The average patient doesn’t exist.Population averages are useful. They help us understand trends, compare outcomes, and ...
09/25/2026

The average patient doesn’t exist.

Population averages are useful. They help us understand trends, compare outcomes, and build the evidence that guides cancer care.

But averages can only tell us so much.

The patient sitting in front of you may be older or younger than the study population. They may have multiple chronic conditions. Their cancer may be at a different stage. Their treatment history, demographics, and overall health may all shape how relevant a population-level outcome is to their individual situation.

That doesn’t make the average wrong.

It makes it incomplete.

In oncology, context matters.

A survival estimate, treatment outcome, or risk calculation becomes more meaningful when we can ask:

What happened among patients who were more like this person?

That means looking beyond diagnosis alone and considering factors such as:

- Age
- Cancer type and stage
- Comorbidities
- Demographics
- Treatment approach

These are among the patient characteristics Capire360 uses to help provide context around real-world oncology outcomes.

The goal isn’t to replace population evidence. It’s to make that evidence more relevant to the individual decision being made.

Because the average tells us about the population.

The patient in front of us is an individual.

At PotentiaMetrics, we believe better decisions begin when real-world evidence is translated into information that reflects the complexity of real patients, not just the average one.

Clinical trials tell us what can happen. Real-world evidence helps us understand what does happen.For decades, clinical ...
09/24/2026

Clinical trials tell us what can happen. Real-world evidence helps us understand what does happen.

For decades, clinical trials have been the foundation of evidence-based cancer care, and they remain essential.

They help researchers determine whether treatments are safe and effective under carefully defined conditions. Randomization, controlled protocols, eligibility criteria, and standardized endpoints allow researchers to answer questions that would be difficult to answer any other way.

But the patients we care for every day don't always look exactly like the patients represented in a clinical trial.

They are older and younger. They have different comorbidities. Different backgrounds. Different disease characteristics. Different treatment histories. And they receive care across different physicians, health systems, and communities.

So once a treatment moves from a clinical trial into routine care, another important question emerges: What happens in the real world?

That's where real-world data and real-world evidence can add another dimension to our understanding of cancer care.

This isn't about choosing between clinical trials and real-world evidence.

They answer different questions. Clinical trials can tell us whether a treatment works in a defined study population under specified conditions. Real-world evidence can help us examine what happens when treatments are used across broader populations and actual care settings, and explore how outcomes may differ based on factors that aren't always fully represented in traditional trials.

Age. Comorbidities. Demographics. Disease characteristics. Treatment patterns.

Those variables matter when we're trying to understand outcomes for the individual patient in front of us.

The FDA's Oncology Center of Excellence is actively advancing the rigorous use of real-world data in oncology. Its Real World Evidence Program focuses on methodology, regulatory policy, scientific collaboration, data quality, and the appropriate use of RWD to generate evidence for oncology product development and patient-centered regulatory decision-making. FDA research priorities also explicitly include developing real-world endpoints that can complement traditional clinical trial data. That's an important distinction.

At PotentiaMetrics, we believe understanding what happens to real people, receiving real care, in real-world settings can provide critical context for healthcare decision-making.

Because the more we understand about outcomes across different patients and different circumstances, the better equipped we are to ask a more personalized question: What has happened to people like me?

Address

901 S. Mopac Expressway, Bldg. 1, Ste. 300
Austin, TX
78746

Alerts

Be the first to know and let us send you an email when PotentiaMetrics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to PotentiaMetrics:

Shortcuts

Share

Nearby computer & electronics services